Kiniksa Pharmaceuticals International, plc Financials

KNSA

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Kiniksa Pharmaceuticals International, plc (KNSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 71/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Kiniksa Pharmaceuticals International, plc has an operating margin of 11.4%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 48/100, indicating healthy but not exceptional operating efficiency. This is up from -10.8% the prior year.

Growth

100

Kiniksa Pharmaceuticals International, plc's revenue surged 60.1% year-over-year to $677.6M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Kiniksa Pharmaceuticals International, plc carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.79, Kiniksa Pharmaceuticals International, plc holds $3.79 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 74/100.

Cash Flow

Kiniksa Pharmaceuticals International, plc converts 20.1% of revenue into free cash flow ($136.4M). This strong cash generation earns a score of 75/100.

Returns

Kiniksa Pharmaceuticals International, plc's ROE of 10.4% shows moderate profitability relative to equity, earning a score of 34/100. This is up from -9.8% the prior year.

Altman Z-Score Safe

12.26

Kiniksa Pharmaceuticals International, plc scores 12.26, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.7B) relative to total liabilities ($196.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

7/9

Kiniksa Pharmaceuticals International, plc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.34x

For every $1 of reported earnings, Kiniksa Pharmaceuticals International, plc generates $2.34 in operating cash flow ($138.0M OCF vs $59.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$677.6M

YoY+60.1%

Kiniksa Pharmaceuticals International, plc generated $677.6M in revenue in fiscal year 2025. This represents an increase of 60.1% from the prior year.

EBITDA

$78.8M

YoY+279.4%

Kiniksa Pharmaceuticals International, plc's EBITDA was $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 279.4% from the prior year.

Net Income

$59.0M

YoY+236.6%

Kiniksa Pharmaceuticals International, plc reported $59.0M in net income in fiscal year 2025. This represents an increase of 236.6% from the prior year.

EPS (Diluted)

$0.75

YoY+225.0%

Kiniksa Pharmaceuticals International, plc earned $0.75 per diluted share (EPS) in fiscal year 2025. This represents an increase of 225.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$136.4M

YoY+436.8%

Kiniksa Pharmaceuticals International, plc generated $136.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 436.8% from the prior year.

Cash & Debt

$165.6M

YoY-9.8%

5Y CAGR+7.7%

Kiniksa Pharmaceuticals International, plc held $165.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

88.5%

YoY+2.9pp

Kiniksa Pharmaceuticals International, plc's gross margin was 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.9 percentage points from the prior year.

Operating Margin

11.4%

YoY+22.2pp

Kiniksa Pharmaceuticals International, plc's operating margin was 11.4% in fiscal year 2025, reflecting core business profitability. This is up 22.2 percentage points from the prior year.

Net Margin

8.7%

YoY+18.9pp

Kiniksa Pharmaceuticals International, plc's net profit margin was 8.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 18.9 percentage points from the prior year.

Return on Equity

10.4%

YoY+20.3pp

5Y CAGR+62.1pp

Kiniksa Pharmaceuticals International, plc's ROE was 10.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$96.9M

YoY-13.2%

5Y CAGR-2.9%

Kiniksa Pharmaceuticals International, plc invested $96.9M in research and development in fiscal year 2025. This represents a decrease of 13.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.6M

YoY+466.1%

5Y CAGR+40.8%

Kiniksa Pharmaceuticals International, plc invested $1.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 466.1% from the prior year.

KNSA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$677.6M+60.1%	$423.2M+56.6%	$270.3M+22.7%	$220.2M+471.2%	$38.5M	N/A
Cost of Revenue	$77.7M+27.5%	$60.9M+82.3%	$33.4M+45.9%	$22.9M+151.6%	$9.1M	N/A
Gross Profit	$599.9M+65.6%	$362.3M+53.0%	$236.9M+20.1%	$197.3M+570.0%	$29.4M	N/A
R&D Expenses	$96.9M-13.2%	$111.6M+46.7%	$76.1M+16.2%	$65.5M-34.0%	$99.3M-11.4%	$112.0M
SG&A Expenses	$196.3M+16.8%	$168.0M+29.8%	$129.4M+32.1%	$98.0M+14.0%	$85.9M+89.6%	$45.3M
Operating Income	$77.2M+269.3%	-$45.6M-81.0%	-$25.2M-357.8%	$9.8M+106.2%	-$156.6M+0.5%	-$157.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$29.9M+324.1%	$7.0M+122.9%	-$30.7M+82.2%	-$172.3M-12543.1%	$1.4M-73.1%	$5.2M
Net Income	$59.0M+236.6%	-$43.2M-406.7%	$14.1M-92.3%	$183.4M+216.1%	-$157.9M+2.1%	-$161.4M
EPS (Diluted)	$0.75+225.0%	$-0.60-400.0%	$0.20-92.3%	$2.60+213.0%	$-2.30+11.9%	$-2.61

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$202.1M+11.8%	$180.9M+15.3%	$156.8M+13.8%	$137.8M+12.4%	$122.5M+9.2%	$112.2M+3.3%	$108.6M+36.0%	$79.9M
Cost of Revenue	$20.9M+3.4%	$20.3M+8.9%	$18.6M+4.1%	$17.9M-0.2%	$17.9M-11.0%	$20.1M+63.2%	$12.3M+16.4%	$10.6M
Gross Profit	$181.2M+12.8%	$160.6M+16.2%	$138.2M+15.2%	$119.9M+14.6%	$104.6M+13.6%	$92.1M-4.4%	$96.3M+39.0%	$69.3M
R&D Expenses	$34.6M+43.2%	$24.2M+28.9%	$18.8M-3.0%	$19.3M-45.1%	$35.2M+35.1%	$26.1M+8.5%	$24.0M-8.8%	$26.3M
SG&A Expenses	$56.8M+15.6%	$49.1M+4.8%	$46.9M+7.7%	$43.5M+7.4%	$40.5M-12.6%	$46.4M+9.4%	$42.4M+9.6%	$38.7M
Operating Income	$19.8M-17.7%	$24.0M+19.2%	$20.2M+51.9%	$13.3M+168.8%	-$19.3M-99.8%	-$9.7M-8154.7%	-$117K+99.3%	-$16.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$9.1M+4.0%	$8.7M+72.9%	$5.0M-28.2%	$7.0M+186.8%	-$8.1M-247.3%	$5.5M-11.6%	$6.2M+81.2%	$3.4M
Net Income	$14.2M-23.0%	$18.4M+3.4%	$17.8M+108.8%	$8.5M+196.1%	-$8.9M+30.0%	-$12.7M-224.8%	-$3.9M+77.9%	-$17.7M
EPS (Diluted)	N/A	$0.230.0%	$0.23+109.1%	$0.11	N/A	$-0.18-200.0%	$-0.06+76.0%	$-0.25

KNSA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$763.6M+31.5%	$580.6M+10.3%	$526.3M+14.5%	$459.7M+97.5%	$232.8M-33.4%	$349.5M
Current Assets	$527.2M+58.9%	$331.8M+20.1%	$276.3M+13.7%	$243.1M+23.7%	$196.4M-41.1%	$333.2M
Cash & Equivalents	$165.6M-9.8%	$183.6M+70.1%	$108.0M-12.0%	$122.7M+0.2%	$122.5M+7.4%	$114.0M
Inventory	$54.9M+108.2%	$26.4M-15.3%	$31.1M+44.1%	$21.6M+487.7%	$3.7M	$0
Accounts Receivable	$15.6M-62.6%	$41.7M+96.2%	$21.3M+68.0%	$12.7M+217.7%	$4.0M	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$196.0M+37.9%	$142.1M+62.5%	$87.5M+37.7%	$63.5M+33.0%	$47.8M+27.3%	$37.5M
Current Liabilities	$139.2M+38.3%	$100.6M+58.0%	$63.7M+35.3%	$47.1M+5.0%	$44.8M+40.8%	$31.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$567.6M+29.5%	$438.4M-0.1%	$438.8M+10.8%	$396.1M+114.1%	$185.0M-40.7%	$311.9M
Retained Earnings	-$462.1M+11.3%	-$521.1M-9.0%	-$477.9M+2.9%	-$492.0M+27.1%	-$675.4M-30.5%	-$517.5M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$763.6M+7.2%	$712.3M+7.7%	$661.1M+10.3%	$599.3M+3.2%	$580.6M+4.5%	$555.3M+2.4%	$542.4M+4.4%	$519.7M
Current Assets	$527.2M+10.9%	$475.5M+13.1%	$420.3M+18.1%	$355.9M+7.3%	$331.8M+6.6%	$311.3M+3.4%	$301.0M+11.2%	$270.6M
Cash & Equivalents	$165.6M-5.3%	$174.9M-8.9%	$192.0M+22.2%	$157.1M-14.4%	$183.6M+88.5%	$97.4M-1.9%	$99.3M-29.6%	$141.1M
Inventory	$54.9M+32.6%	$41.4M-14.1%	$48.2M+118.3%	$22.1M-16.3%	$26.4M-8.1%	$28.7M-17.7%	$34.9M+27.8%	$27.3M
Accounts Receivable	$15.6M-69.9%	$51.7M+62.1%	$31.9M-20.4%	$40.1M-4.0%	$41.7M+67.6%	$24.9M+21.7%	$20.5M+27.9%	$16.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$196.0M+10.8%	$176.9M+6.5%	$166.1M+17.1%	$141.8M-0.2%	$142.1M+20.1%	$118.3M+10.2%	$107.3M+22.3%	$87.8M
Current Liabilities	$139.2M+12.6%	$123.6M+4.9%	$117.8M+21.1%	$97.3M-3.3%	$100.6M+4.9%	$96.0M+13.8%	$84.3M+31.3%	$64.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$567.6M+6.0%	$535.4M+8.2%	$495.0M+8.2%	$457.5M+4.3%	$438.4M+0.3%	$437.0M+0.4%	$435.1M+0.7%	$431.9M
Retained Earnings	-$462.1M+3.0%	-$476.3M+3.7%	-$494.8M+3.5%	-$512.6M+1.6%	-$521.1M-1.7%	-$512.3M-2.5%	-$499.6M-0.8%	-$495.7M

KNSA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$138.0M+437.1%	$25.7M+93.1%	$13.3M+129.1%	$5.8M+104.6%	-$126.3M+7.5%	-$136.5M
Capital Expenditures	$1.6M+466.1%	$277K+113.1%	$130K+23.8%	$105K-74.7%	$415K+46.6%	$283K
Free Cash Flow	$136.4M+436.8%	$25.4M+92.9%	$13.2M+131.0%	$5.7M+104.5%	-$126.7M+7.4%	-$136.8M
Investing Cash Flow	-$189.0M-601.7%	$37.7M+227.5%	-$29.6M-265.9%	-$8.1M-106.3%	$128.6M+648.7%	-$23.4M
Financing Cash Flow	$33.0M+169.2%	$12.3M+720.5%	$1.5M-40.6%	$2.5M-57.2%	$5.9M-97.4%	$227.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$53.9M+60.0%	$33.7M+19.9%	$28.1M+25.8%	$22.3M+18.9%	$18.8M+939.4%	-$2.2M-143.3%	$5.2M+29.6%	$4.0M
Capital Expenditures	$633K-5.7%	$671K+306.7%	$165K+66.7%	$99K-48.7%	$193K	$0	$0-100.0%	$84K
Free Cash Flow	$53.3M+61.4%	$33.0M+18.2%	$27.9M+25.6%	$22.2M+19.6%	$18.6M+930.8%	-$2.2M-143.3%	$5.2M+32.4%	$3.9M
Investing Cash Flow	-$70.8M-12.8%	-$62.8M-1516.1%	-$3.9M+92.5%	-$51.5M-178.9%	$65.3M+1128.6%	-$6.3M+86.4%	-$46.8M-283.3%	$25.5M
Financing Cash Flow	$7.7M-35.6%	$11.9M+11.2%	$10.7M+286.5%	$2.8M+29.2%	$2.1M-68.0%	$6.7M+3857.9%	-$178K-104.9%	$3.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KNSA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	88.5%+2.9pp	85.6%-2.0pp	87.6%-2.0pp	89.6%+13.2pp	76.4%	N/A
Operating Margin	11.4%+22.2pp	-10.8%-1.5pp	-9.3%-13.8pp	4.4%+410.8pp	-406.4%	N/A
Net Margin	8.7%+18.9pp	-10.2%-15.4pp	5.2%-78.1pp	83.3%+493.0pp	-409.7%	N/A
Return on Equity	10.4%+20.3pp	-9.8%-13.1pp	3.2%-43.1pp	46.3%+131.6pp	-85.4%-33.6pp	-51.7%
Return on Assets	7.7%+15.2pp	-7.4%-10.1pp	2.7%-37.2pp	39.9%+107.7pp	-67.8%-21.7pp	-46.2%
Current Ratio	3.79+0.5	3.30-1.0	4.34-0.8	5.16+0.8	4.38-6.1	10.46
Debt-to-Equity	0.35+0.0	0.32+0.1	0.20+0.0	0.16-0.1	0.26+0.1	0.12
FCF Margin	20.1%+14.1pp	6.0%+1.1pp	4.9%+2.3pp	2.6%+331.3pp	-328.8%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	89.6%+0.8pp	88.8%+0.7pp	88.1%+1.1pp	87.0%+1.6pp	85.4%+3.3pp	82.1%-6.6pp	88.7%+1.9pp	86.8%
Operating Margin	9.8%-3.5pp	13.3%+0.4pp	12.9%+3.2pp	9.6%+25.4pp	-15.8%-7.1pp	-8.6%-8.5pp	-0.1%+20.6pp	-20.7%
Net Margin	7.0%-3.2pp	10.2%-1.2pp	11.4%+5.2pp	6.2%+13.5pp	-7.2%+4.1pp	-11.3%-7.7pp	-3.6%+18.6pp	-22.2%
Return on Equity	2.5%-0.9pp	3.4%-0.2pp	3.6%+1.7pp	1.9%+3.9pp	-2.0%+0.9pp	-2.9%-2.0pp	-0.9%+3.2pp	-4.1%
Return on Assets	1.9%-0.7pp	2.6%-0.1pp	2.7%+1.3pp	1.4%+2.9pp	-1.5%+0.8pp	-2.3%-1.6pp	-0.7%+2.7pp	-3.4%
Current Ratio	3.79-0.1	3.85+0.3	3.57-0.1	3.66+0.4	3.30+0.1	3.24-0.3	3.57-0.6	4.21
Debt-to-Equity	0.35+0.0	0.330.0	0.34+0.0	0.31-0.0	0.32+0.1	0.27+0.0	0.25+0.0	0.20
FCF Margin	26.4%+8.1pp	18.3%+0.4pp	17.8%+1.7pp	16.1%+1.0pp	15.2%+17.2pp	-2.0%-6.8pp	4.8%-0.1pp	4.9%

Similar Companies

Hutchmed (China) Limited HCM

$2.6B

Supernus Pharma SUPN

$3.0B

Indivior Pharmaceuticals Inc. INDV

$3.7B

Bausch Health Companies Inc BHC

$2.1B

Alvotech ALVO

$1.1B

Frequently Asked Questions

What is Kiniksa Pharmaceuticals International, plc's annual revenue?

Kiniksa Pharmaceuticals International, plc (KNSA) reported $677.6M in total revenue for fiscal year 2025. This represents a 60.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Kiniksa Pharmaceuticals International, plc's revenue growing?

Kiniksa Pharmaceuticals International, plc (KNSA) revenue grew by 60.1% year-over-year, from $423.2M to $677.6M in fiscal year 2025.

Is Kiniksa Pharmaceuticals International, plc profitable?

Yes, Kiniksa Pharmaceuticals International, plc (KNSA) reported a net income of $59.0M in fiscal year 2025, with a net profit margin of 8.7%.

What is Kiniksa Pharmaceuticals International, plc's EBITDA?

Kiniksa Pharmaceuticals International, plc (KNSA) had EBITDA of $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kiniksa Pharmaceuticals International, plc's gross margin?

Kiniksa Pharmaceuticals International, plc (KNSA) had a gross margin of 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Kiniksa Pharmaceuticals International, plc's operating margin?

Kiniksa Pharmaceuticals International, plc (KNSA) had an operating margin of 11.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Kiniksa Pharmaceuticals International, plc's net profit margin?

Kiniksa Pharmaceuticals International, plc (KNSA) had a net profit margin of 8.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Kiniksa Pharmaceuticals International, plc's return on equity (ROE)?

Kiniksa Pharmaceuticals International, plc (KNSA) has a return on equity of 10.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Kiniksa Pharmaceuticals International, plc's free cash flow?

Kiniksa Pharmaceuticals International, plc (KNSA) generated $136.4M in free cash flow during fiscal year 2025. This represents a 436.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kiniksa Pharmaceuticals International, plc's operating cash flow?

Kiniksa Pharmaceuticals International, plc (KNSA) generated $138.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Kiniksa Pharmaceuticals International, plc's total assets?

Kiniksa Pharmaceuticals International, plc (KNSA) had $763.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Kiniksa Pharmaceuticals International, plc's capital expenditures?

Kiniksa Pharmaceuticals International, plc (KNSA) invested $1.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Kiniksa Pharmaceuticals International, plc spend on research and development?

Kiniksa Pharmaceuticals International, plc (KNSA) invested $96.9M in research and development during fiscal year 2025.

What is Kiniksa Pharmaceuticals International, plc's current ratio?

Kiniksa Pharmaceuticals International, plc (KNSA) had a current ratio of 3.79 as of fiscal year 2025, which is generally considered healthy.

What is Kiniksa Pharmaceuticals International, plc's debt-to-equity ratio?

Kiniksa Pharmaceuticals International, plc (KNSA) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kiniksa Pharmaceuticals International, plc's return on assets (ROA)?

Kiniksa Pharmaceuticals International, plc (KNSA) had a return on assets of 7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Kiniksa Pharmaceuticals International, plc's Altman Z-Score?

Kiniksa Pharmaceuticals International, plc (KNSA) has an Altman Z-Score of 12.26, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Kiniksa Pharmaceuticals International, plc's Piotroski F-Score?

Kiniksa Pharmaceuticals International, plc (KNSA) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kiniksa Pharmaceuticals International, plc's earnings high quality?

Kiniksa Pharmaceuticals International, plc (KNSA) has an earnings quality ratio of 2.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Kiniksa Pharmaceuticals International, plc?

Kiniksa Pharmaceuticals International, plc (KNSA) scores 71 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.